

Octavian Vasiliu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/643655/publications.pdf>

Version: 2024-02-01

48
papers

79
citations

2258059

3
h-index

1720034

7
g-index

51
all docs

51
docs citations

51
times ranked

17
citing authors

#	ARTICLE	IF	CITATIONS
1	Current Status of Evidence for a New Diagnosis: Food Addiction-A Literature Review. <i>Frontiers in Psychiatry</i> , 2021, 12, 824936.	2.6	28
2	Investigational Drugs for the Treatment of Depression (Part 1): Monoaminergic, Orexinergic, GABA-Ergic, and Anti-Inflammatory Agents. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	15
3	Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms. <i>Frontiers in Psychiatry</i> , 2021, 12, 786171.	2.6	12
4	Quality of life impairments and stress coping strategies during the Covid-19 pandemic isolation and quarantine. <i>A Web-based survey.</i> , 2021, 124, 10-21.		9
5	Current Trends and Perspectives in the Immune Therapy for Substance Use Disorders. <i>Frontiers in Psychiatry</i> , 2022, 13, 882491.	2.6	8
6	Quetiapine XR as Add-on to Antidepressants in Treatment-resistant Late-life Major Depression. <i>European Psychiatry</i> , 2017, 41, S144-S144.	0.2	1
7	Health-related Quality of Life in Old Age Institutionalized Patients with Neurocognitive Disorders. <i>European Psychiatry</i> , 2017, 41, S666-S666.	0.2	1
8	F57. EVALUATION OF SUICIDE RISK IN SCHIZOPHRENIA SPECTRUM DISORDERS - A LITERATURE REVIEW. <i>Schizophrenia Bulletin</i> , 2019, 45, S276-S277.	4.3	1
9	Diagnostic and treatment features of work stress-related disorders in healthcare professionals in the context of COVID-19 pandemic. <i>Psihiatru Ro</i> , 2021, 3, 22.	0.0	1
10	Modern approaches in the treatment of compulsive eating disorders. <i>Psihiatru Ro</i> , 2019, 2, 24.	0.0	1
11	Efficacy analysis of the third generation of cognitive-behavioral therapies – a narrative literature review (II). <i>Psihiatru Ro</i> , 2020, 4, 34.	0.0	1
12	Third generation cognitive-behavioral therapies for major depressive disorder- a literature review. <i>European Psychiatry</i> , 2021, 64, S325-S325.	0.2	1
13	P.3.c.074 Aripiprazole switch-on in chronic schizophrenia with atypical antipsychotics associated weight gain. <i>European Neuropsychopharmacology</i> , 2008, 18, S446.	0.7	0
14	Quality of life assessment in patients diagnosed with bipolar disorder and alcohol dependence. <i>International Clinical Psychopharmacology</i> , 2011, 26, e29.	1.7	0
15	Familial history of psychotic disorders in patients with bipolar I and II disorder. <i>International Clinical Psychopharmacology</i> , 2011, 26, e29-e30.	1.7	0
16	Psychoactive substance induced manic episodes in a population of young patients—a case series. <i>International Clinical Psychopharmacology</i> , 2011, 26, e30.	1.7	0
17	Quetiapine efficacy and tolerability in bipolar ii disorder with comorbid cluster c personality disorder. <i>International Clinical Psychopharmacology</i> , 2011, 26, e29.	1.7	0
18	Cognitive Behavioral Therapy in Internet Addiction—A Case Series. <i>European Psychiatry</i> , 2017, 41, s784-s784.	0.2	0

#	ARTICLE	IF	CITATIONS
19	Pharmacological management of antipsychotic-induced obesity – a systematic literature review. <i>European Neuropsychopharmacology</i> , 2017, 27, S928-S929.	0.7	0
20	T114. IMPROVING THERAPEUTIC ADHERENCE IN SCHIZOPHRENIA SPECTRUM DISORDERS - FROM NURSING APPROACHES TO NEW TECHNOLOGIES. <i>Schizophrenia Bulletin</i> , 2019, 45, S247-S248.	4.3	0
21	F56. NALTREXONE AS MAINTENANCE TREATMENT IN OPIOID USE DISORDER COMORBID WITH SCHIZOPHRENIA - A CASE SERIES. <i>Schizophrenia Bulletin</i> , 2019, 45, S276-S276.	4.3	0
22	S55. THERAPEUTIC MANAGEMENT OF PATIENTS DIAGNOSED WITH SCHIZOPHRENIA AND MAJOR NEUROCOGNITIVE DISORDER DUE TO ALZHEIMER'S DISEASE - A CASE SERIES. <i>Schizophrenia Bulletin</i> , 2019, 45, S327-S328.	4.3	0
23	S56. PERSONALITY DISORDERS DIAGNOSED IN PATIENTS WITH SCHIZOPHRENIA SPECTRUM DISORDERS - A RETROSPECTIVE ANALYSIS. <i>Schizophrenia Bulletin</i> , 2019, 45, S328-S328.	4.3	0
24	T197. TREATMENT STRATEGIES FOR ULTRA-RESISTANT SCHIZOPHRENIAS. <i>Schizophrenia Bulletin</i> , 2020, 46, S306-S307.	4.3	0
25	M194. THE USE OF NOVEL PSYCHOACTIVE SUBSTANCES IN THE PRODROMAL PHASE OF SCHIZOPHRENIA- A CASE SERIES. <i>Schizophrenia Bulletin</i> , 2020, 46, S210-S210.	4.3	0
26	P.623 Efficacy and tolerability of naltrexone in patients with Internet gaming disorder and comorbid alcohol use disorder. <i>European Neuropsychopharmacology</i> , 2020, 40, S352-S353.	0.7	0
27	P.624 Evaluation of the efficacy of combined, nalmefene and cognitive behavioral therapy, for gambling disorder. <i>European Neuropsychopharmacology</i> , 2020, 40, S353-S354.	0.7	0
28	P.658 Calcium channel alpha-2-delta ligands as an add-on strategy to antidepressants in generalized anxiety disorder and major depressive disorder dual diagnosis. <i>European Neuropsychopharmacology</i> , 2020, 40, S372-S373.	0.7	0
29	S196. TRANSCRANIAL MAGNETIC STIMULATION IN SCHIZOPHRENIA WITH PROMINENT NEGATIVE SYMPTOMS- A REVIEW OF THE LITERATURE. <i>Schizophrenia Bulletin</i> , 2020, 46, S113-S113.	4.3	0
30	M193. CHANGES IN THEORY OF MIND DETECTED IN SCHIZOPHRENIA SPECTRUM DISORDERS- A LITERATURE REVIEW. <i>Schizophrenia Bulletin</i> , 2020, 46, S209-S210.	4.3	0
31	T196. THERAPEUTIC MANAGEMENT IN MULTIPLE SCLEROSIS AND SCHIZOPHRENIA SPECTRUM DISORDERS DUAL DIAGNOSIS. <i>Schizophrenia Bulletin</i> , 2020, 46, S306-S306.	4.3	0
32	Evidence-based pharmacological strategies for gambling disorder. <i>Psihiatru Ro</i> , 2021, 3, 10.	0.0	0
33	Considerations on the quality of life in patients with dual diagnosis of depressive disorder and alcohol dependence. <i>Romanian Medical Journal</i> , 2015, 62, 339-343.	0.1	0
34	Reintegration of Schizophrenia Diagnosed Patients in Social Environment through Art Therapy-A Pilot Study. , 2017, , .		0
35	Improving Quality of Life in Caregivers of Alzheimer Dementia Patients- A Stepwise Approach. , 2017, , .		0
36	Social Factors for Major Depressive Disorder Negative Prognosis in Young Patients. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
37	Pharmacological therapy of post-stroke depression. Psihiatru Ro, 2019, 2, 18.	0.0	0
38	Therapeutic management of substance use disorders (I). Psihiatru Ro, 2020, 1, 5.	0.0	0
39	Therapeutic management of substance use disorders (II). Psihiatru Ro, 2020, 1, 14.	0.0	0
40	Therapeutic management of major neurocognitive disorder due to Alzheimer's disease*. Psihiatru Ro, 2020, 3, 37.	0.0	0
41	Efficacy analysis of the third generation of cognitive-behavioral therapies – a narrative literature review. Psihiatru Ro, 2020, 3, 42.	0.0	0
42	Physical activity and maintaining of the proteome in the aging process - are these footsteps on the way to longevity?. Health Sports & Rehabilitation Medicine, 2021, 22, 120-126.	0.0	0
43	Psychotherapies for neurocognitive disorder due to Alzheimer's disease- the current level of evidence. European Psychiatry, 2021, 64, S420-S420.	0.2	0
44	Evaluation of executive dysfunction in clinical practice- pragmatic challenges and solutions. European Psychiatry, 2021, 64, S508-S508.	0.2	0
45	Mindfulness-based cognitive therapy for major depressive disorder- a literature review. European Psychiatry, 2021, 64, S494-S494.	0.2	0
46	Evidence-based therapeutic management of binge-eating disorder. European Psychiatry, 2021, 64, S351-S351.	0.2	0
47	P.0378 Pharmacological treatment for type I bipolar disorder in late life – a retrospective analysis. European Neuropsychopharmacology, 2021, 53, S275-S276.	0.7	0
48	Transnosographic analysis of executive dysfunction – clinical, psychometric and therapeutic dimensions. Psihiatru Ro, 2022, 2, 18.	0.0	0